BHC stock icon

Bausch Health
BHC

$6.21
0.32%

Market Cap: $2.28B

 

About: Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Employees: 20,270

0
Funds holding %
of 6,710 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% less funds holding

Funds holding: 231 [Q1] → 230 (-1) [Q2]

0.48% less ownership

Funds ownership: 76.99% [Q1] → 76.51% (-0.48%) [Q2]

3% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 40

18% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 71

30% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 7 (-3) [Q2]

33% less capital invested

Capital invested by funds: $2.93B [Q1] → $1.96B (-$972M) [Q2]

72% less call options, than puts

Call options by funds: $34.3M | Put options by funds: $124M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
52%
downside
Avg. target
$6.63
7%
upside
High target
$8.50
37%
upside

4 analyst ratings

positive
0%
neutral
75%
negative
25%
RBC Capital
Douglas Miehm
71% 1-year accuracy
5 / 7 met price target
37%upside
$8.50
Sector Perform
Maintained
2 Aug 2024
Piper Sandler
David Amsellem
61% 1-year accuracy
22 / 36 met price target
52%downside
$3
Underweight
Downgraded
2 Aug 2024
Truist Securities
Gregory Fraser
50% 1-year accuracy
3 / 6 met price target
13%upside
$7
Hold
Maintained
25 Jul 2024
Raymond James
Michael Freeman
0 / 0 met price target
29%upside
$8
Market Perform
Initiated
10 Jul 2024

Financial journalist opinion